Enhancing the Outcome of Cell Therapy for Cardiac Repair

Chavakis, Emmanouil; Koyanagi, Masamichi; Dimmeler, Stefanie

doi:10.1161/circulationaha.109.901405

Cited by 142 publications

(133 citation statements)

References 144 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…So far, a wide range of different cell sources have been utilized in engineering cardiac tissues. 6,9 For instance, primary cardiomyocytes, 3 8,67 and mesenchymal stem cells (MSCs) 3,8,9 have been used in efforts to regenerate the damaged myocardium. Because of the limited access to primary cardiomyocytes and their minimal capability for expansion in vitro, alternative cell sources were used as mentioned above.…”

Section: Directing Stem Cell Differentiation Into Cardiac Lineagementioning

confidence: 99%

“…9 Therapeutic potential of cells can be augmented by pre-treating them with growth factors or cytokines to increase their attachment, survival, migration and differentiation capacity. 9 For example, interleukin-8/Gro-a, stromal derived factor-1, vascular endothelial growth factor (VEGF), IGF-1, hepatocyte growth factor, fibroblast growth factor (FGF), integrin-linked kinase, Akt and glycogen synthase kinase have been extensively used to enhance viability and engraftment potential of delivered cells for cardiac therapy. 9 The long-term goal is to differentiate the delivered stem cells into functional cardiomyocytes for regeneration of the damaged tissue.…”

Section: Growth Factor Delivery For Cardiac Tissue Engineeringmentioning

confidence: 99%

“…9 For example, interleukin-8/Gro-a, stromal derived factor-1, vascular endothelial growth factor (VEGF), IGF-1, hepatocyte growth factor, fibroblast growth factor (FGF), integrin-linked kinase, Akt and glycogen synthase kinase have been extensively used to enhance viability and engraftment potential of delivered cells for cardiac therapy. 9 The long-term goal is to differentiate the delivered stem cells into functional cardiomyocytes for regeneration of the damaged tissue. To enhance the differentiation of stem cells, cytokines and growth factors such as IGF-1, FGF, Wnt-5a, Wnt11, bone morphogenetic proteins 2 and 4, transforming growth factor-beta1 have previously been utilized.…”

Section: Growth Factor Delivery For Cardiac Tissue Engineeringmentioning

confidence: 99%

“…6,7 Direct injection of cells into the cardiac muscle has been used as a method of delivering cells into the infarcted tissue. 4,5,8,9 In vivo, this approach has been shown to achieve some success in regaining muscle function after MI. 10,11 However, B90% of the injected cells die after implantation, demonstrating the importance of vasculature and appropriate tissue microarchitecture for cardiac tissue regeneration.…”

Section: Introductionmentioning

confidence: 99%

“…2,4,9,12,13 Although tissue engineering platforms have been successfully used for engineering of avascular organs, generating artificial substitutes for highly vascularized cardiac tissues remains remarkably challenging. 14 Because of their highly tunable features, engineered hydrogels have been used to address these limitations.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Hydrogels for cardiac tissue engineering

et al. 2014

View full text Add to dashboard Cite

Section: Directing Stem Cell Differentiation Into Cardiac Lineagementioning

confidence: 99%

Section: Growth Factor Delivery For Cardiac Tissue Engineeringmentioning

confidence: 99%

Section: Growth Factor Delivery For Cardiac Tissue Engineeringmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Hydrogels for cardiac tissue engineering

et al. 2014

View full text Add to dashboard Cite

Generation of a Human Cardiac Patch Based on a Reendothelialized Biological Scaffold (BioVaSc)

et al. 2017

View full text Add to dashboard Cite

Despite improvements in acute care, ischemic heart disease remains the major cause of death worldwide. [1] For the treatment of heart infarction or heart failure, stem cell therapies have emerged as a therapeutic option. Although data from first clinical trials revealed promising safety profiles with moderate Although there are improvements in acute care, ischemic heart disease is the major cause of death worldwide. As a treatment for heart failure or heart infarction, stem cell therapies emerged as a potential therapeutic option. First results have shown moderate improvements and have revealed several limitations, such as an insufficient retention, homing, and engraftment of the cells. These drawbacks result in a loss of cells shortly after implantation. To overcome these hurdles, a human cardiac patch is developed in this work, using a biological collagen-based vascularized scaffold (BioVaSc ® ). Endothelial cells are cultured in the pre-existing vascular structure to establish a physiological blood-tissue interface. A co-culture of fibroblasts, mesenchymal stem cells, and induced-pluripotent-stem-cell-derived cardiomyocytes is seeded on the vascularized scaffold. After two weeks, physiological cardiac functions and expression of cardiac-specific markers is detected. Moreover, physiological beating rates as well as responsiveness to drug treatment and electrical stimulation is observed. Bioreactor culture facilitates long-term culture up to four months. Due to its tissue characteristics, the patch constitutes a promising tool for drug development, in addition to its potential in clinical applications.

show abstract

Stimuli Responsive Delivery Vehicles for Cardiac Microtissue Transplantation

Pedrón

Lierop

Horstman

et al. 2011

Adv Funct Materials

View full text Add to dashboard Cite

Cell transplantation has emerged as the most promising therapy for restoring the scarred myocardium in the treatment of heart failure. However, clinical effi cacy of (stem) cell therapies is still limited by poor retention rate and survival of injected cells in the ischemic tissue. Here we present a new strategy to deliver microtissues in the treatment of heart dysfunction in order to improve the retention, survival, and integration of the delivered cells. For this purpose, we developed stimuli responsive biodegradable polymer constructs consisting of a thin fi lm of thermosensitive hydrogel coupled to a thin fi lm of non-responsive polymer. Due to the temperature responsive swelling behavior of the hydrogel layer, the bilayer polymer constructs can roll or unroll at will. Therefore they can potentially be used for effi cient encapsulation and protection of cell clusters during delivery, while under physiological conditions, the constructs, named cell wraps, can unroll and expose the delivered microtissue to the ischemic tissue.

show abstract

Enhancing the Outcome of Cell Therapy for Cardiac Repair

Cited by 142 publications

References 144 publications

Hydrogels for cardiac tissue engineering

Hydrogels for cardiac tissue engineering

Generation of a Human Cardiac Patch Based on a Reendothelialized Biological Scaffold (BioVaSc)

Stimuli Responsive Delivery Vehicles for Cardiac Microtissue Transplantation

Contact Info

Product

Resources

About